[go: up one dir, main page]

UA105766C2 - Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин - Google Patents

Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин

Info

Publication number
UA105766C2
UA105766C2 UAA201014025A UAA201014025A UA105766C2 UA 105766 C2 UA105766 C2 UA 105766C2 UA A201014025 A UAA201014025 A UA A201014025A UA A201014025 A UAA201014025 A UA A201014025A UA 105766 C2 UA105766 C2 UA 105766C2
Authority
UA
Ukraine
Prior art keywords
cyclodextrin
vitamin
pharmaceutical composition
strontium salt
amount
Prior art date
Application number
UAA201014025A
Other languages
English (en)
Russian (ru)
Inventor
Брійо Жіль
Квено Кзавьє
Пуарьє Сесіль
Па Жан-Манюель
Original Assignee
Ле Лаборатуар Сервьє
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41719206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105766(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ле Лаборатуар Сервьє filed Critical Ле Лаборатуар Сервьє
Publication of UA105766C2 publication Critical patent/UA105766C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується фармацевтичної композиції, яка містить, як активні інгредієнти, сіль стронцію і вітамін D і, як наповнювачі, циклодекстрин, а також один або більше інших інертних, нетоксичних, фармацевтично прийнятних наповнювачів або носіїв, в якій масове співвідношення між кількістю вітаміну D і кількістю циклодекстрину становить від 1/40 до 1/800.
UAA201014025A 2009-11-27 2010-11-24 Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин UA105766C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905706A FR2953139B1 (fr) 2009-11-27 2009-11-27 Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine

Publications (1)

Publication Number Publication Date
UA105766C2 true UA105766C2 (uk) 2014-06-25

Family

ID=41719206

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201014025A UA105766C2 (uk) 2009-11-27 2010-11-24 Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин

Country Status (31)

Country Link
US (1) US20110130370A1 (uk)
EP (1) EP2335704A1 (uk)
JP (1) JP2011111458A (uk)
KR (1) KR101278935B1 (uk)
CN (1) CN102078620A (uk)
AP (1) AP2010005490A0 (uk)
AR (1) AR079160A1 (uk)
AU (1) AU2010241527B2 (uk)
BR (1) BRPI1004685A2 (uk)
CA (1) CA2723119C (uk)
CL (1) CL2010001260A1 (uk)
CO (1) CO6280058A1 (uk)
CU (1) CU20100230A7 (uk)
EA (1) EA018460B1 (uk)
EC (1) ECSP10010622A (uk)
FR (1) FR2953139B1 (uk)
GE (1) GEP20135734B (uk)
HN (1) HN2010002518A (uk)
IL (1) IL209348A0 (uk)
MA (1) MA32363B1 (uk)
MX (1) MX2010012566A (uk)
MY (1) MY158261A (uk)
NZ (1) NZ589513A (uk)
PE (1) PE20110407A1 (uk)
SG (1) SG171542A1 (uk)
SV (1) SV2010003744A (uk)
TW (1) TW201200136A (uk)
UA (1) UA105766C2 (uk)
UY (1) UY33039A (uk)
WO (1) WO2011064474A1 (uk)
ZA (1) ZA201008230B (uk)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882048C (en) 2006-02-03 2020-03-24 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
EP2679228B1 (en) 2006-06-21 2018-03-21 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
KR101759244B1 (ko) 2007-04-25 2017-07-18 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
WO2009047644A2 (en) 2007-04-25 2009-04-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
SI2796457T1 (sl) 2009-11-27 2016-10-28 Genzyme Corporation Genz 112638 za zdravljenje Gaucherjeve ali Fabryjeve bolezni v kombinirani terapiji
SI2552484T1 (sl) 2010-03-29 2020-07-31 Opko Ireland Global Holdings, Ltd. Postopki in sestavki za znižanje ravni paratiroidnega hormona
CN102525975B (zh) * 2011-12-14 2013-06-19 天津药物研究院药业有限责任公司 雷奈酸锶口腔崩解片及其制备方法
CN102626420B (zh) * 2012-04-13 2014-06-25 深圳大学 一种含有锶、钙和维生素d的混合制剂
EP2756841B1 (en) * 2013-01-21 2015-05-13 Galenicum Health S.L. Pharmaceutical compositions comprising an acid salt
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103142623B (zh) * 2013-03-21 2014-04-16 青岛正大海尔制药有限公司 骨化三醇和雷尼酸锶的混悬颗粒及其制备方法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10532065B2 (en) 2014-12-19 2020-01-14 Nagasaki University Bisphosphonic acid derivative and application for same
CA3018019A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
WO2018084959A2 (en) 2016-09-30 2018-05-11 Nelson Deanna J Pharmaceutical quality strontium l-lactate
KR102805246B1 (ko) * 2017-04-25 2025-05-09 버크 인스티튜트 포 리서치 온 에이징 수명 및 건강수명을 연장시키기 위한 제제
WO2019004984A2 (en) * 2017-05-29 2019-01-03 Biofarma Ilac Sanayi Ve Ticaret A.S. PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
CN109276710A (zh) * 2018-11-23 2019-01-29 中国医学科学院药用植物研究所海南分所 一种增加骨密度的组合物及其制备方法和用途
CN112370429A (zh) * 2019-10-21 2021-02-19 广州富诺营养科技有限公司 一种直压型有机钙维生素d3咀嚼片及其制备方法
CN114452259A (zh) * 2021-07-28 2022-05-10 安徽旺盛添加剂有限公司 一种维生素d微囊钙片及其制备方法
CN119055788A (zh) * 2023-05-31 2024-12-03 葛兰素史克消费保健（美国）控股有限责任公司 活性成分络合物及其制备方法
WO2024246793A1 (en) * 2023-05-31 2024-12-05 Haleon Us Holdings Llc Active ingredient complex and method of making thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52130904A (en) * 1976-04-26 1977-11-02 Teijin Ltd Stabilization of vitamin d#
HU177586B (en) * 1978-12-19 1981-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing stable inclusion complexes of vitamine d with cyclodextrin
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2651497B1 (fr) 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
CN1110275A (zh) * 1994-04-06 1995-10-18 福建省药品检验所 一种维生素D与羟丙基-β-环糊精的包合物
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
ATE348116T1 (de) * 1999-11-12 2007-01-15 Freres Roquette Kristalline mischungen aus teilmethylestern des beta-cyclodextrins und verwandten verbindungen
EP1155043A1 (en) * 1999-12-23 2001-11-21 Cerestar Holding B.V. Stabilized cyclodextrin complexes
JP2003268005A (ja) * 2002-03-14 2003-09-25 Medorekkusu:Kk 包接体の製造法
PT2266585E (pt) * 2003-05-07 2013-07-09 Osteologix As Sais de estrôncio hidrossolúveis para uso no tratamento de afeções cartilagíneas e/ou ósseas
EP1534305B9 (en) 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
JP5049589B2 (ja) * 2003-05-07 2012-10-17 オステオロジックス エイ／エス ストロンチウム塩含有の放出制御組成物
EP1632594B1 (en) * 2003-05-30 2010-07-07 Mitsui Chemicals, Inc. Fiber for artificial hair
EP1643978A1 (en) * 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
AU2005256317B2 (en) * 2004-06-25 2011-09-15 Mokwalo Spf S.A. Compositions comprising strontium and vitamin D and uses thereof
CN101018586B (zh) * 2004-06-25 2014-08-27 莫克瓦洛Spf有限公司 含锶和维生素d的组合物及其用途
WO2006105196A2 (en) * 2005-03-28 2006-10-05 Bioresponse, L.L.C. Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
DE102005017775A1 (de) * 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
US20070218111A1 (en) * 2006-03-16 2007-09-20 Western Holdings, Llc Strontium compositions for bones
CN1823764A (zh) * 2006-03-27 2006-08-30 重庆医药工业研究院有限责任公司 一种含有雷奈酸锶和维生素d药物组合物
FR2899895B1 (fr) 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제

Also Published As

Publication number Publication date
TW201200136A (en) 2012-01-01
EA201001710A2 (ru) 2011-06-30
AU2010241527A1 (en) 2011-06-16
EP2335704A1 (fr) 2011-06-22
GEP20135734B (en) 2013-01-25
PE20110407A1 (es) 2011-07-02
MY158261A (en) 2016-09-30
ECSP10010622A (es) 2011-06-30
CU20100230A7 (es) 2012-06-29
FR2953139A1 (fr) 2011-06-03
UY33039A (es) 2011-04-29
IL209348A0 (en) 2011-02-28
AR079160A1 (es) 2011-12-28
JP2011111458A (ja) 2011-06-09
SG171542A1 (en) 2011-06-29
EA018460B1 (ru) 2013-08-30
NZ589513A (en) 2012-06-29
CA2723119C (fr) 2013-08-06
CA2723119A1 (fr) 2011-05-27
AU2010241527B2 (en) 2013-12-19
FR2953139B1 (fr) 2012-04-13
ZA201008230B (en) 2011-07-27
US20110130370A1 (en) 2011-06-02
BRPI1004685A2 (pt) 2013-03-05
EA201001710A3 (ru) 2011-08-30
KR20110059546A (ko) 2011-06-02
WO2011064474A1 (fr) 2011-06-03
AP2010005490A0 (en) 2010-12-31
HN2010002518A (es) 2012-09-03
MA32363B1 (fr) 2011-06-01
MX2010012566A (es) 2011-05-26
KR101278935B1 (ko) 2013-06-28
CO6280058A1 (es) 2011-05-20
CL2010001260A1 (es) 2012-02-17
CN102078620A (zh) 2011-06-01
SV2010003744A (es) 2011-03-15

Similar Documents

Publication Publication Date Title
UA105766C2 (uk) Фармацевтична композиція, яка містить сіль стронцію, вітамін d і циклодекстрин
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
UA105229C2 (uk) Фармацевтичний склад
MX2011012122A (es) Derivados de tiofeno.
MX348653B (es) Derivados ester de acido boronico ciclico y sus usos terapeuticos.
IN2012DN01233A (uk)
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
MX2015015356A (es) Formulacion estabilizada de pemetrexed.
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
EP3626253A3 (en) Stable formulations of linaclotide
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
TW200942524A (en) Novel aminomethyl benzene derivatives
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2014013851A (es) Composiciones farmaceuticas topicas que comprenden terbinafina y urea.
MX2009012472A (es) Combinacion que comprende acido pirrolidona-5-carboxilico y por lo menos un compuesto de citrulina, arginina y asparragina, y su uso en el tratamiento de dermatitis atopica.
PH12013500371A1 (en) Therapeutic agent for pain
MX356373B (es) Composiciones que comprenden un agente antibacterial y tazobactam.
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
PH12013501896A1 (en) Use of a sprayable composition comprising ambroxol
WO2012010938A3 (en) Pharmaceutical composition of cefditoren pivoxil
ZA201008022B (en) Pharmaceutical compositions for the treatment of warts
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
TW201129660A (en) Dermal absorption agent comprising felbinac